COYA THERAPEUTICS, INC. COMMON STOCK

NASDAQ: COYA (Coya Therapeutics, Inc.)

Kemas kini terakhir: 02 Dec, 10:28PM

5.98

-0.26 (-4.17%)

Penutupan Terdahulu 6.24
Buka 6.30
Jumlah Dagangan 192,175
Purata Dagangan (3B) 186,575
Modal Pasaran 125,128,248
Harga / Jualan (P/S) 25.61
Harga / Buku (P/B) 4.71
Julat 52 Minggu
4.65 (-22%) — 8.29 (38%)
Tarikh Pendapatan 12 Nov 2025
Margin Operasi (TTM) -2,976.89%
EPS Cair (TTM) -1.07
Pertumbuhan Hasil Suku Tahunan (YOY) 103.30%
Nisbah Semasa (MRQ) 8.84
Aliran Tunai Operasi (OCF TTM) -15.26 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -10.29 M
Pulangan Atas Aset (ROA TTM) -32.06%
Pulangan Atas Ekuiti (ROE TTM) -52.11%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Bercampur
Biotechnology (Global) Bercampur Bercampur
Stok Coya Therapeutics, Inc. Menurun Bercampur

AISkor Stockmoo

1.4
Konsensus Penganalisis 4.0
Aktiviti Orang Dalam NA
Volatiliti Harga 2.0
Purata Bergerak Teknikal 0.0
Osilator Teknikal -0.5
Purata 1.38

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
COYA 125 M - - 4.71
RVMD 15 B - - 9.42
RNA 11 B - - 5.70
RYTM 8 B - - 46.99
CDTX 7 B - - 16.47
KYMR 6 B - - 4.89

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Core
% Dimiliki oleh Orang Dalam 7.02%
% Dimiliki oleh Institusi 28.08%
Julat 52 Minggu
4.65 (-22%) — 8.29 (38%)
Julat Harga Sasaran
14.00 (134%) — 16.00 (167%)
Tinggi 16.00 (BTIG, 167.56%) Beli
Median 15.00 (150.84%)
Rendah 14.00 (Chardan Capital, 134.11%) Beli
Purata 15.00 (150.84%)
Jumlah 3 Beli
Harga Purata @ Panggilan 5.95
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
D. Boral Capital 09 Dec 2025 15.00 (150.84%) Beli 6.02
12 Nov 2025 15.00 (150.84%) Beli 6.09
Chardan Capital 14 Nov 2025 14.00 (134.11%) Beli 5.87
17 Sep 2025 14.00 (134.11%) Beli 5.41
BTIG 13 Nov 2025 16.00 (167.56%) Beli 5.96
30 Sep 2025 15.00 (150.84%) Beli 5.70

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
09 Dec 2025 Pengumuman Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
25 Nov 2025 Pengumuman Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
12 Nov 2025 Pengumuman Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
04 Nov 2025 Pengumuman Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
27 Oct 2025 Pengumuman Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
24 Oct 2025 Pengumuman Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock
23 Oct 2025 Pengumuman Coya Therapeutics Announces Proposed Public Offering of Common Stock
07 Oct 2025 Pengumuman Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function
29 Sep 2025 Pengumuman Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia
22 Sep 2025 Pengumuman Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis
16 Sep 2025 Pengumuman Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda